Table 1 Demographic data of patients with refractory inflammatory myopathies
PatientDiagnosisSex/AgeDisease duration (years)Previous treatmentConcomitant treatment, daily doses
1PMF/495Pred, MTX, AZA, MMF, CiA, SSZPred 15 mg, MTX 7.5 mg/week
2PM*F/527Pred, MTX, AZA, CyXAZA 100 mg
3PMM/534Pred, MTX, AZA, IVIG, CyXPred 17.5 mg, AZA 200 mg
4PM*F/765Pred, MTX, AZAPred 2.5 mg, MTX 15 mg/week
5PMF/564Pred, MTX, AZA, Cy A, CyX, IVIGPred 5 mg, MTX 15 mg/week
6DM*M/5010Pred, AMA, MTX, CiAMTX 15 mg/week
7DMM/4420Pred, MTX, AZA, IVIG, CiAPred 5 mg, AZA 150 mg, IVIG
8DMF/541Pred, AZAPred 8 mg, MTX 20 mg/week, AZA 150 mg
9DMF/743Pred, MTX, AZA, IVIGPred 10 mg, AZA 150 mg
10IBM*F/654Pred, MTX, AZA, IVIGMTX 15 mg/week
11IBMM/744Pred, MTX, IVIGMTX 15 mg/week
12IBMF/606Pred, MTX, AZA, IVIGPred 3.75 mg, MTX 7.5 mg/week
13IBMM/644Pred, MTX, CiAPred 5 mg, MTX 15 mg/week
  • *Also Sj√∂gren syndrome.

  • AMA, antimalarial drug; AZA, azathioprine; CiA, ciclosporine A; CyX, cyclophosphamide; DM, dermatomyositis; F, female; IBM, inclusion body myositis; IVIG, intravenous immunoglobulin; M, male; MMF, mycophenolate mofetil; MTX, methotrexate; PM, polymyositis; Pred, prednisolone; SSZ, sulfasalazine.